A Study in Patients With Erectile Dysfunction
Launched by ELI LILLY AND COMPANY · May 11, 2010
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • History of Erectile Dysfunction (ED) of at least 3 months duration.
- • Anticipate having the same adult female sexual partner during the study.
- • Agree not to use any other treatment for ED and to participate in recording responses to questionnaires and other instruments used in this study.
- Exclusion Criteria:
- • Previous or current treatment with tadalafil or any other phosphodiesterase type 5 (PDE5) inhibitor.
- • ED caused by other primary sexual disorders, history of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection, or history of penile implant or clinically significant penile deformity.
- • ED caused by untreated or inadequately treated endocrine disease.
- • Current treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens.
- • Severe renal or hepatic impairment, history of malignant hypertension.
- • Presence or history of specific heart conditions.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alcorcon, , Spain
Porto, , Portugal
Thessaloniki, , Greece
Barcelona, , Spain
Madrid, , Spain
Lille, , France
Marseille, , France
Heraklion, , Greece
Patras, , Greece
Rennes, , France
Leverkusen, , Germany
Vigo, , Spain
Lyon, , France
Larissa, , Greece
Kutno, , Poland
Durham, County Durham, United Kingdom
Marburg, , Germany
Muehlacker, , Germany
Leipzig, , Germany
Legionowo, , Poland
Aravaca, , Spain
Carpentras, , France
Holzminden, , Germany
Warburg, , Germany
Chambery, , France
La Bouexiere, , France
Montpellier, , France
Murs Erigne, , France
Nantes, , France
Toulouse, , France
Giengen, , Germany
Grevenbroich, , Germany
Koblenz, , Germany
Luebeck, , Germany
Lublin, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Bucharest, , Romania
Cluj Napoca, , Romania
Coslada, , Spain
Gijon, , Spain
Málaga, , Spain
San Sebastian De Los Reyes, , Spain
Fowey, Cornwall, United Kingdom
Plymouth, Devon, United Kingdom
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials